Safety and Activity of Digoxin With Decitabine in Adult AML and MDS
Status:
Terminated
Trial end date:
2019-03-11
Target enrollment:
Participant gender:
Summary
The primary hypothesis is that digoxin can be safely added to decitabine and will increase
the response rates in medically unfit patients with newly diagnosed AML/MDS or those with
relapsed/refractory AML/MDS. Furthermore, it is hypothesized that the addition of digoxin to
decitabine will result in distinct epigenetic alterations in AML/MDS patients.